{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T05:13:48Z","timestamp":1794719628468,"version":"4.9.1"},"reference-count":122,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2005,6,16]],"date-time":"2005-06-16T00:00:00Z","timestamp":1118880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,7,28]]},"DOI":"10.1111\/j.1365-2249.2005.02834.x","type":"journal-article","created":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T10:01:14Z","timestamp":1126605674000},"page":"1-11","source":"Crossref","is-referenced-by-count":285,"title":["Clinical uses of intravenous immunoglobulin"],"prefix":"10.1093","volume":"142","author":[{"given":"S","family":"Jolles","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology, Royal Free Hospital London, UK"},{"name":"National Institute for Medical Research, Mill Hill, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W A C","family":"Sewell","sequence":"additional","affiliation":[{"name":"Path Links Immunology, Scunthorpe General Hospital, North Lincolnshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S A","family":"Misbah","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Churchill Hospital, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,6,16]]},"reference":[{"key":"2022010711172949700_b1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"2022010711172949700_b2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2567.2002.01545.x","article-title":"Immunomodulatory action of intravenous immunoglobulin","volume":"107","author":"Sewell","year":"2002","journal-title":"Immunology"},{"key":"2022010711172949700_b3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1172\/JCI116240","article-title":"Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens","volume":"91","author":"Takei","year":"1993","journal-title":"J Clin Invest"},{"key":"2022010711172949700_b4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0731-7085(99)00087-4","article-title":"An enzyme immunoassay to determine the levels of specific antibodies toward bacterial surface antigens in human immunoglobulin preparations and blood serum","volume":"20","author":"Lamari","year":"1999","journal-title":"J Pharm Biomed Anal"},{"key":"2022010711172949700_b5","first-page":"133","article-title":"Evidence for immunosuppression by high-dose gammaglobulin","volume":"15","author":"Kawada","year":"1987","journal-title":"Exp Hematol"},{"key":"2022010711172949700_b6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-3083.1993.tb02591.x","article-title":"Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro","volume":"38","author":"Klaesson","year":"1993","journal-title":"Scand J Immunol"},{"key":"2022010711172949700_b7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF00920789","article-title":"Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro","volume":"12","author":"Van Schaik","year":"1992","journal-title":"J Clin Immunol"},{"key":"2022010711172949700_b8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0165-5728(01)00243-0","article-title":"Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis","volume":"114","author":"Aktas","year":"2001","journal-title":"J Neuroimmunol"},{"key":"2022010711172949700_b9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"2022010711172949700_b10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1067\/mai.2001.118796","article-title":"Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis","volume":"108","author":"Trautmann","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl.","key":"2022010711172949700_b11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jnnp.57.Suppl.15","article-title":"In vitro effects of polyvalent immunoglobulin for intravenous use","volume":"57","author":"Van Schaik","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2022010711172949700_b12","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.4049\/jimmunol.161.7.3781","article-title":"Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway","volume":"161","author":"Prasad","year":"1998","journal-title":"J Immunol"},{"key":"2022010711172949700_b13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.8755-8920.2000.440603.x","article-title":"Intravenous immunoglobulin therapy influences T cell adhesion to extracellular matrix in women with a history of recurrent spontaneous abortions","volume":"44","author":"Jerzak","year":"2000","journal-title":"Am J Reprod Immunol"},{"key":"2022010711172949700_b14","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood.V93.11.3624","article-title":"Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg)","volume":"93","author":"Vassilev","year":"1999","journal-title":"Blood"},{"key":"2022010711172949700_b15","doi-asserted-by":"crossref","first-page":"14210","DOI":"10.1073\/pnas.0402183101","article-title":"Natural antibodies sustain differentiation and maturation of human dendritic cells","volume":"101","author":"Bayry","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022010711172949700_b16","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1182\/blood.V100.3.1055","article-title":"Gamma-globulins prepared from sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response","volume":"100","author":"Semple","year":"2002","journal-title":"Blood"},{"key":"2022010711172949700_b17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0009-8981(88)90210-0","article-title":"Enzyme-linked immunosorbent assay (ELISA) for human tumor necrosis factor (hTNF)","volume":"176","author":"Abe","year":"1988","journal-title":"Clin Chim Acta"},{"key":"2022010711172949700_b18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.1994.tb00854.x","article-title":"Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy","volume":"139","author":"Abe","year":"1994","journal-title":"Immunol Rev"},{"key":"2022010711172949700_b19","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1365-2141.1995.tb08404.x","article-title":"In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins","volume":"89","author":"Toungouz","year":"1995","journal-title":"Br J Haematol"},{"key":"2022010711172949700_b20","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1073\/pnas.89.8.3325","article-title":"Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain","volume":"89","author":"Marchalonis","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022010711172949700_b21","first-page":"269","article-title":"Anti-CD4 activity of normal human immunoglobulin G for therapeutic use (intravenous immunoglobulin, IVIg)","volume":"1","author":"Hurez","year":"1994","journal-title":"Ther Immunol"},{"key":"2022010711172949700_b22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2249.1993.tb03407.x","article-title":"Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg)","volume":"92","author":"Vassilev","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"2022010711172949700_b23","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1056\/NEJM198205273062102","article-title":"Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin","volume":"306","author":"Fehr","year":"1982","journal-title":"N Engl J Med"},{"key":"2022010711172949700_b24","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1046\/j.1365-2141.1996.393931.x","article-title":"Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes","volume":"92","author":"Ericson","year":"1996","journal-title":"Br J Haematol"},{"key":"2022010711172949700_b25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1074-7613(03)00080-3","article-title":"Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease","volume":"18","author":"Bruhns","year":"2003","journal-title":"Immunity"},{"key":"2022010711172949700_b26","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","article-title":"Inhibition of maturation and function of dendritic cells by intravenous im-munoglobulin","volume":"101","author":"Bayry","year":"2003","journal-title":"Blood"},{"key":"2022010711172949700_b27","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/blood.V84.7.2136.2136","article-title":"Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo","volume":"84","author":"Aukrust","year":"1994","journal-title":"Blood"},{"key":"2022010711172949700_b28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1128\/iai.55.3.547-554.1987","article-title":"Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits","volume":"55","author":"Iwata","year":"1987","journal-title":"Infect Immun"},{"key":"2022010711172949700_b29","first-page":"211","article-title":"Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG","volume":"79","author":"Andersson","year":"1993","journal-title":"Immunology"},{"key":"2022010711172949700_b30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-065X.1994.tb00855.x","article-title":"Pooled human IgG modulates cytokine production in lymphocytes and monocytes","volume":"139","author":"Andersson","year":"1994","journal-title":"Immunol Rev"},{"key":"2022010711172949700_b31","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/eji.1830250521","article-title":"Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin)","volume":"25","author":"Ruiz de Souza","year":"1995","journal-title":"Eur J Immunol"},{"key":"2022010711172949700_b32","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/BF00920238","article-title":"Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in vivo","volume":"13","author":"Ling","year":"1993","journal-title":"J Clin Immunol"},{"key":"2022010711172949700_b33","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0091-6749(99)70466-5","article-title":"Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin","volume":"103","author":"Spahn","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"2022010711172949700_b34","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.V62.2.480.480","article-title":"Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura","volume":"62","author":"Bussel","year":"1983","journal-title":"Blood"},{"key":"2022010711172949700_b35","first-page":"133","article-title":"Intravenous Immunoglobulins in the Third Millenium.","author":"Van Mirre","year":"2004"},{"key":"2022010711172949700_b36","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1046\/j.1365-3083.1998.00386.x","article-title":"High-dose intravenous immunoglobulin treatment activates complement in vivo","volume":"48","author":"Mollnes","year":"1998","journal-title":"Scand J Immunol"},{"key":"2022010711172949700_b37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nm836","article-title":"F(ab)\u20322-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins","volume":"9","author":"Basta","year":"2003","journal-title":"Nat Med"},{"key":"2022010711172949700_b38","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/0140-6736(93)91784-J","article-title":"Immunologically active proteins in intravenous immunoglobulin","volume":"342","author":"Lam","year":"1993","journal-title":"Lancet"},{"key":"2022010711172949700_b39","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1046\/j.1365-3083.1996.d01-350.x","article-title":"Contribution of stabilizing agents present in intravenous immunoglobulin preparations to modulation of mononuclear cell proliferation in vitro","volume":"44","author":"Alder","year":"1996","journal-title":"Scand J Immunol"},{"key":"2022010711172949700_b40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0042-9007.2004.00391.x","article-title":"Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on","volume":"86","author":"Bierling","year":"2004","journal-title":"Vox Sang"},{"key":"2022010711172949700_b41","first-page":"373","article-title":"Intravenous Immunoglobulins in the Third Millenium.","author":"Provan","year":"2004"},{"key":"2022010711172949700_b42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2141.2003.04162.x","article-title":"Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors","volume":"121","author":"Delgado","year":"2003","journal-title":"Br J Haematol"},{"key":"2022010711172949700_b43","doi-asserted-by":"crossref","first-page":"F6","DOI":"10.1136\/fn.88.1.F6","article-title":"Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn","volume":"88","author":"Gottstein","year":"2003","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"2022010711172949700_b44","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"2022010711172949700_b45","first-page":"17","article-title":"Intravenous immune globulin in chronic lymphocytic leukaemia","volume":"97","author":"Gamm","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"2022010711172949700_b46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM199107113250202","article-title":"Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia","volume":"325","author":"Weeks","year":"1991","journal-title":"N Engl J Med"},{"key":"2022010711172949700_b47","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","article-title":"Prophylactic antibiotics for the prevention of early infection in multiple myeloma","volume":"100","author":"Oken","year":"1996","journal-title":"Am J Med"},{"key":"2022010711172949700_b48","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002063.pub2","article-title":"Intravenous immunoglobulin for Guillain\u2013Barre syndrome","volume-title":"Cochrane Database Syst Rev","author":"Hughes","year":"2004"},{"key":"2022010711172949700_b49","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain\u2013Barre syndrome: randomised trial","volume":"363","author":"Van Koningsveld","year":"2004","journal-title":"Lancet"},{"key":"2022010711172949700_b50","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","article-title":"Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study","volume":"55","author":"Federico","year":"2000","journal-title":"Neurology"},{"key":"2022010711172949700_b51","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s004150200013","article-title":"Disease severity in multifocal motor neuropathy and its association with the response to immunoglobulin treatment","volume":"249","author":"Van den Berg-Vos","year":"2002","journal-title":"J Neurol"},{"key":"2022010711172949700_b52","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann Neurol"},{"key":"2022010711172949700_b53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","article-title":"Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy","volume":"56","author":"Mendell","year":"2001","journal-title":"Neurology"},{"key":"2022010711172949700_b54","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"2022010711172949700_b55","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"2022010711172949700_b56","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","article-title":"Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert\u2013Eaton myasthenic syndrome","volume":"47","author":"Bain","year":"1996","journal-title":"Neurology"},{"key":"2022010711172949700_b57","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","article-title":"High-dose intravenous immune globulin for stiff\u2013person syndrome","volume":"345","author":"Dalakas","year":"2001","journal-title":"N Engl J Med"},{"key":"2022010711172949700_b58","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1468-1331.2002.00501.x","article-title":"Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis","volume":"9","author":"Sorensen","year":"2002","journal-title":"Eur J Neurol"},{"key":"2022010711172949700_b59","article-title":"Intravenous immunoglobulins for multiple sclerosis","volume-title":"Cochrane Database Syst Rev","author":"Gray","year":"2003"},{"key":"2022010711172949700_b60","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","article-title":"Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial","volume":"364","author":"Hommes","year":"2004","journal-title":"Lancet"},{"key":"2022010711172949700_b61","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0090-1229(82)90022-8","article-title":"Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial","volume":"22","author":"Ammann","year":"1982","journal-title":"Clin Immunol Immunopathol"},{"key":"2022010711172949700_b62","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-101-4-435","article-title":"Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease","volume":"101","author":"Cunningham-Rundles","year":"1984","journal-title":"Ann Intern Med"},{"key":"2022010711172949700_b63","first-page":"237","article-title":"Intravenous immunoglobulin therapy for antibody deficiency","volume":"36","author":"Nolte","year":"1979","journal-title":"Clin Exp Immunol"},{"key":"2022010711172949700_b64","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(87)90494-6","article-title":"High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease","volume":"1","author":"Roifman","year":"1987","journal-title":"Lancet"},{"key":"2022010711172949700_b65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0090-1229(87)90123-1","article-title":"Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment","volume":"43","author":"Bernatowska","year":"1987","journal-title":"Clin Immunol Immunopathol"},{"key":"2022010711172949700_b66","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-135-3-200108070-00008","article-title":"The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial","volume":"135","author":"Eijkhout","year":"2001","journal-title":"Ann Intern Med"},{"key":"2022010711172949700_b67","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF01486738","article-title":"Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency","volume":"20","author":"Pruzanski","year":"1996","journal-title":"Inflammation"},{"key":"2022010711172949700_b68","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1067\/mai.2002.124999","article-title":"Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency","volume":"109","author":"Busse","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"2022010711172949700_b69","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0928-8244(03)00304-3","article-title":"Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia","volume":"40","author":"Aghamohammadi","year":"2004","journal-title":"FEMS Immunol Med Microbiol"},{"key":"2022010711172949700_b70","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1053\/rmed.2000.1020","article-title":"Respiratory disorders in common variable immunodeficiency","volume":"95","author":"Martinez Garcia","year":"2001","journal-title":"Respir Med"},{"key":"2022010711172949700_b71","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0091-6749(99)70085-0","article-title":"Pulmonary abnormalities in patients with primary hypogammaglobulinemia","volume":"104","author":"Kainulainen","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"2022010711172949700_b72","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000361.pub2","article-title":"Intravenous immunoglobulin for preventing infection in preterm and\/or low-birth-weight infants","volume-title":"Cochrane Database Syst Rev","author":"Ohlsson","year":"2004"},{"key":"2022010711172949700_b73","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001239.pub2","article-title":"Intravenous immunoglobulin for suspected or subsequently proven infection in neonates","volume-title":"Cochrane Database Syst Rev","author":"Ohlsson","year":"2004"},{"key":"2022010711172949700_b74","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/00015550310020549","article-title":"Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts","volume":"83","author":"Jolles","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"2022010711172949700_b75","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1034\/j.1398-9995.2000.00829.x","article-title":"Are IVIG for chronic unremitting urticaria effective?","volume":"55","author":"Asero","year":"2000","journal-title":"Allergy"},{"key":"2022010711172949700_b76","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1046\/j.1365-2133.2000.03395.x","article-title":"High-dose intravenous immune globulin is also effective in linear IgA disease","volume":"142","author":"Kroiss","year":"2000","journal-title":"Br J Dermatol"},{"key":"2022010711172949700_b77","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2133.1998.02033.x","article-title":"Intravenous immunoglobulin in autoimmune chronic urticaria","volume":"138","author":"O'Donnell","year":"1998","journal-title":"Br J Dermatol"},{"key":"2022010711172949700_b78","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1067\/mjd.2000.104001","article-title":"Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg)","volume":"43","author":"Lister","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"2022010711172949700_b79","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1365-2133.2003.05682.x","article-title":"Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin","volume":"149","author":"Kulczycki","year":"2003","journal-title":"Br J Dermatol"},{"key":"2022010711172949700_b80","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2230.2004.01518.x","article-title":"Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin","volume":"29","author":"Karim","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"2022010711172949700_b81","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1191\/1352458504ms987cr","article-title":"Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a","volume":"10","author":"Kumar","year":"2004","journal-title":"Mult Scler"},{"key":"2022010711172949700_b82","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.61.1.59","article-title":"Intravenous immunoglobulins control scleromyxoedema","volume":"61","author":"Righi","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2022010711172949700_b83","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00003226-200301000-00021","article-title":"Annular crystalline keratopathy in association with immunoglobulin therapy for pyoderma gangrenosum","volume":"22","author":"Budde","year":"2003","journal-title":"Cornea"},{"key":"2022010711172949700_b84","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1067\/mjd.2003.172","article-title":"Superficial granulomatous pyoderma treated with intravenous immunoglobulin","volume":"48","author":"Dobson","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"2022010711172949700_b85","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s001050051003","article-title":"[Post-traumatic pyoderma gangrenosum: combination therapy with intravenous immunoglobulins and systemic corticosteroids]","volume":"50","author":"Gleichmann","year":"1999","journal-title":"Hautarzt"},{"key":"2022010711172949700_b86","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/0190-9622(95)90218-X","article-title":"Efficacy of human intravenous immune globulin in pyoderma gangrenosum","volume":"32","author":"Gupta","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"2022010711172949700_b87","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/095466301750163527","article-title":"The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum","volume":"12","author":"Hagman","year":"2001","journal-title":"J Dermatolog Treat"},{"key":"2022010711172949700_b88","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0190-9622(98)70052-0","article-title":"Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin","volume":"39","author":"Dirschka","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"2022010711172949700_b89","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1089\/thy.1994.4.399","article-title":"Pretibial myxedema and high-dose intravenous immunoglobulin treatment","volume":"4","author":"Antonelli","year":"1994","journal-title":"Thyroid"},{"key":"2022010711172949700_b90","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1046\/j.1365-2230.2003.01232_3.x","article-title":"Lack of response of elephantiasic pretibial myxoedema to treatment with high-dose intravenous immunoglobulins","volume":"28","author":"Terheyden","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"2022010711172949700_b91","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1046\/j.1365-2133.2002.04753.x","article-title":"Psoriasis: response to high-dose intravenous immunoglobulin in three patients","volume":"147","author":"Gurmin","year":"2002","journal-title":"Br J Dermatol"},{"issue":"Suppl. 1","key":"2022010711172949700_b92","first-page":"63","article-title":"Kawasaki disease. Mucocutaneous lymph node syndrome or MCLS","volume":"32","author":"Kawasaki","year":"1982","journal-title":"Acta Pathol Jpn"},{"key":"2022010711172949700_b93","first-page":"178","article-title":"[Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]","volume":"16","author":"Kawasaki","year":"1967","journal-title":"Arerugi"},{"key":"2022010711172949700_b94","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1542\/peds.54.3.271","article-title":"A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan","volume":"54","author":"Kawasaki","year":"1974","journal-title":"Pediatrics"},{"key":"2022010711172949700_b95","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","article-title":"A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome","volume":"324","author":"Newburger","year":"1991","journal-title":"N Engl J Med"},{"key":"2022010711172949700_b96","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJM198608073150601","article-title":"The treatment of Kawasaki syndrome with intravenous gamma globulin","volume":"315","author":"Newburger","year":"1986","journal-title":"N Engl J Med"},{"key":"2022010711172949700_b97","article-title":"Intravenous immunoglobulin for the treatment of Kawasaki disease in children","volume-title":"Cochrane Database Syst Rev","author":"Oates-Whitehead","year":"2003"},{"key":"2022010711172949700_b98","first-page":"430","article-title":"High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis","volume":"83","author":"Campione","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"2022010711172949700_b99","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"2022010711172949700_b100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"2022010711172949700_b101","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0190-9622(99)70183-0","article-title":"The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile","volume":"40","author":"Amagai","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"2022010711172949700_b102","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0025-7125(05)70415-6","article-title":"The blistering diseases","volume":"82","author":"Scott","year":"1998","journal-title":"Med Clin North Am"},{"key":"2022010711172949700_b103","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1517\/13543784.13.8.1019","article-title":"Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy","volume":"13","author":"Ahmed","year":"2004","journal-title":"Expert Opin Invest Drugs"},{"key":"2022010711172949700_b104","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2249.2002.01967.x","article-title":"High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders","volume":"129","author":"Jolles","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"2022010711172949700_b105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clim.2003.11.002","article-title":"A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies","volume":"111","author":"Letko","year":"2004","journal-title":"Clin Immunol"},{"key":"2022010711172949700_b106","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/0140-6736(91)92797-6","article-title":"Treatment of systemic vasculitis with pooled intravenous immunoglobulin","volume":"337","author":"Jayne","year":"1991","journal-title":"Lancet"},{"key":"2022010711172949700_b107","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"Qjm"},{"key":"2022010711172949700_b108","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/rheumatology\/35.11.1150","article-title":"Intravenous immunoglobulin as sole therapy for systemic vasculitis","volume":"35","author":"Jayne","year":"1996","journal-title":"Br J Rheumatol"},{"key":"2022010711172949700_b109","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/ndt\/16.2.403","article-title":"Cryoglobulinaemic vasculitis caused by intravenous immunoglobulin treatment","volume":"16","author":"Odum","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"2022010711172949700_b110","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1191\/096120399678841007","article-title":"A study of 20 SLE patients with intravenous immunoglobulin\u2013clinical and serologic response","volume":"8","author":"Levy","year":"1999","journal-title":"Lupus"},{"key":"2022010711172949700_b111","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(99)01575-5","article-title":"Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis","volume":"354","author":"Boletis","year":"1999","journal-title":"Lancet"},{"key":"2022010711172949700_b112","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2022010711172949700_b113","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/515199","article-title":"Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome \u2013 a comparative observational study. The Canadian Streptococcal Study Group","volume":"28","author":"Kaul","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2022010711172949700_b114","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.4049\/jimmunol.156.8.3057","article-title":"Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production","volume":"156","author":"Norrby-Teglund","year":"1996","journal-title":"J Immunol"},{"key":"2022010711172949700_b115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1076\/0927-3948(200003)811-SFT049","article-title":"Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy","volume":"8","author":"LeHoang","year":"2000","journal-title":"Ocul Immunol Inflamm"},{"key":"2022010711172949700_b116","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0002-9394(99)00029-X","article-title":"The treatment of refractory uveitis with intravenous immunoglobulin","volume":"127","author":"Rosenbaum","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"2022010711172949700_b117","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1542\/peds.86.6.955","article-title":"Human immunoglobulins for intravenous use: comparison of available preparations for group B streptococcal antibody levels, opsonic activity, and efficacy in animal models","volume":"86","author":"Givner","year":"1990","journal-title":"Pediatrics"},{"key":"2022010711172949700_b118","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1423-0410.1980.tb02342.x","article-title":"IgG subclasses in human gamma-globulin preparations for intravenous use and their reactivity with staphylococcus protein A","volume":"38","author":"Skvaril","year":"1980","journal-title":"Vox Sang"},{"key":"2022010711172949700_b119","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000460851","article-title":"Characterization of various immunoglobulin preparations for intravenous application. II. Complement activation and binding to staphylococcus protein A","volume":"42","author":"Romer","year":"1982","journal-title":"Vox Sang"},{"key":"2022010711172949700_b120","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0022-3476(95)70233-4","article-title":"Comparative safety and efficacy of two immune globulin products in Kawasaki disease","volume":"126","author":"Rosenfeld","year":"1995","journal-title":"J Pediatr"},{"key":"2022010711172949700_b121","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2249.2004.02412.x","article-title":"Increased risk of adverse events when changing intravenous immunoglobulin preparations","volume":"136","author":"Ameratunga","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"2022010711172949700_b122","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","article-title":"Risks associated with the use of intravenous immunoglobulin","volume":"17","author":"Pierce","year":"2003","journal-title":"Transfus Med Rev"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2005.02834.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/142\/1\/1\/42078249\/j.1365-2249.2005.02834.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/142\/1\/1\/42078249\/j.1365-2249.2005.02834.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T12:43:35Z","timestamp":1683204215000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/142\/1\/1\/6440398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,16]]},"references-count":122,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,6,16]]},"published-print":{"date-parts":[[2005,7,28]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2005.02834.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,10]]},"published":{"date-parts":[[2005,6,16]]}}}